What it's for (Indications)
- Chlorpheniramine + Paracetamol is indicated for the symptomatic relief of various conditions associated with the common cold, influenza (flu), and allergic rhinitis.
- These conditions typically manifest with a constellation of symptoms including sneezing, rhinorrhea (runny nose), watery eyes (lacrimation), nasal congestion, fever, headache, and generalized body aches or malaise.
- The antihistaminic component, chlorpheniramine, effectively targets allergic symptoms by reducing histamine-mediated responses, while paracetamol acts as a potent analgesic and antipyretic to alleviate pain and reduce fever.
- This combination product is designed to provide comprehensive, multi-symptom relief, thereby improving patient comfort and functional capacity during the course of illness.
- It is generally recommended for short-term symptomatic management only and does not treat the underlying cause of the condition.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage recommendations for chlorpheniramine + paracetamol must be strictly adhered to, as prescribed by a healthcare professional, or as detailed in the product information leaflet. For adults and adolescents 12 years of age and older, the typical oral dose is 1 to 2 tablets or capsules, administered every 4 to 6 hours as needed. It is imperative that the total daily dose does not exceed the maximum recommended limits for either active ingredient. Specifically, the maximum daily dose for paracetamol from all sources should not exceed 4 grams (4000 mg) within a 24-hour period for healthy adults, or 3 grams (3000 mg) for individuals with pre-existing liver conditions or chronic alcohol consumption, to minimize the risk of hepatotoxicity. For chlorpheniramine, the maximum daily dose generally should not exceed 24 mg in adults. Pediatric dosing for children under 12 years of age must be carefully determined by a physician, based on age and weight, strictly following specific product guidelines or medical advice to prevent accidental overdose. Patients must be explicitly advised against concurrent use of other medications containing paracetamol to avoid exceeding the safe daily limit. |
Safety & Warnings
Common Side Effects
- The combination of chlorpheniramine and paracetamol can lead to a spectrum of side effects, primarily stemming from the individual pharmacological profiles of each active ingredient.
- Common side effects associated with chlorpheniramine include central nervous system depression, manifesting as significant drowsiness, sedation, dizziness, impaired coordination, and blurred vision.
- Anticholinergic effects such as dry mouth, thickened bronchial secretions, urinary retention, and constipation may also be observed.
- In some individuals, particularly children, paradoxical excitation, restlessness, or insomnia may occur.
- Serious, though rare, side effects attributable to chlorpheniramine can include cardiovascular effects (e.
- g.
- , hypotension, palpitations, tachycardia), blood dyscrasias (e.
- g.
- , agranulocytosis, hemolytic anemia), and severe allergic reactions including anaphylaxis.
- For paracetamol, at therapeutic doses, side effects are generally mild.
- However, overdose can lead to severe and potentially fatal hepatotoxicity.
- Other rare but serious side effects of paracetamol include severe dermatological reactions such as Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP), as well as blood disorders like thrombocytopenia or agranulocytosis.
- Patients should be instructed to discontinue the medication and seek immediate medical attention if any serious or persistent side effects, including unusual fatigue, yellowing of skin/eyes, or skin rash, are experienced.
Serious Warnings
- Black Box Warning: The U.S. Food and Drug Administration (FDA) has mandated a Black Box Warning for all paracetamol (acetaminophen)-containing products, including combination medications such as chlorpheniramine + paracetamol, due to the serious and potentially life-threatening risks associated with its use. This warning highlights two critical safety concerns: 1. **Risk of Severe Liver Damage (Hepatotoxicity)**: Accidental overdose of paracetamol is a leading cause of acute liver failure. This often occurs when individuals unknowingly exceed the maximum recommended daily dose or concurrently use multiple products containing paracetamol. The risk of severe, and potentially fatal, liver damage is significantly increased in individuals with pre-existing liver disease, those who consume alcohol regularly, or when the maximum daily dose is exceeded. Patients must be explicitly warned against taking more than the prescribed amount and cautioned about the presence of paracetamol in other over-the-counter and prescription medications. 2. **Risk of Severe Skin Reactions**: Rarely, paracetamol can cause serious and potentially fatal dermatological reactions, including Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP). These severe skin reactions can occur at any time during treatment and may be accompanied by fever, flu-like symptoms, or blistering. Patients should be instructed to discontinue the medication immediately and seek urgent medical attention at the first appearance of a skin rash, mucosal lesions, or any other sign of hypersensitivity.
- Patients utilizing this medication must be thoroughly advised regarding the potential for significant central nervous system depression, including pronounced drowsiness and impaired mental alertness, due to the chlorpheniramine component.
- Consequently, caution is paramount when performing tasks requiring full mental capacity, such as driving a vehicle or operating heavy machinery.
- Concomitant use of alcohol, sedatives, tranquilizers, or other central nervous system depressants should be strictly avoided due to the additive depressant effects, which can be severe.
- Individuals with pre-existing medical conditions, including narrow-angle glaucoma, prostatic hypertrophy, bladder neck obstruction, symptomatic benign prostatic hyperplasia, asthma, or chronic obstructive pulmonary disease, should exercise extreme caution or avoid this medication entirely due to the anticholinergic effects of chlorpheniramine.
- A critical warning pertains to paracetamol: the risk of severe hepatotoxicity (liver damage), particularly when doses exceed the recommended maximum or when combined with chronic alcohol consumption or pre-existing liver disease.
- Patients must be explicitly warned against taking other medications that contain paracetamol to prevent accidental overdose.
- Individuals with hepatic impairment, malnutrition, or those consuming three or more alcoholic drinks daily should consult a physician before use.
- Furthermore, rare but serious dermatological reactions can occur with paracetamol, necessitating immediate discontinuation and medical consultation at the first sign of rash or other hypersensitivity reactions.
- Use in elderly patients warrants careful monitoring due to increased susceptibility to anticholinergic side effects, sedation, and potential for paradoxical excitation.
How it Works (Mechanism of Action)
The therapeutic efficacy of the chlorpheniramine + paracetamol combination product is derived from the distinct pharmacological mechanisms of its two active components, addressing multiple symptoms. Chlorpheniramine maleate is a first-generation alkylamine antihistamine that functions as a potent, competitive antagonist of histamine H1 receptors. By blocking the binding of histamine at these receptors, chlorpheniramine effectively attenuates the inflammatory and allergic responses mediated by histamine, thereby reducing symptoms such as sneezing, rhinorrhea, pruritus, and watery eyes. Its lipophilic nature allows it to readily cross the blood-brain barrier, which contributes to its characteristic sedative and anticholinergic side effects. Paracetamol (acetaminophen), conversely, primarily exerts its analgesic and antipyretic effects through actions within the central nervous system. While its precise mechanism remains an area of ongoing research, it is believed to selectively inhibit prostaglandin synthesis, predominantly via modulation of cyclooxygenase (COX) enzymes, particularly COX-2, or a potential COX-3 variant, within the brain and spinal cord. This central inhibition of prostaglandin production leads to an elevation of the pain threshold and direct action on the hypothalamic heat-regulating center, resulting in a reduction in pain perception and a lowering of elevated body temperature, without significant peripheral anti-inflammatory activity or inhibition of platelet aggregation.
Commercial Brands (Alternatives)
No other brands found for this formula.